Financhill
Sell
32

GMRE Quote, Financials, Valuation and Earnings

Last price:
$6.28
Seasonality move :
733.98%
Day range:
$6.27 - $6.43
52-week range:
$6.06 - $10.46
Dividend yield:
13.36%
P/E ratio:
209.67x
P/S ratio:
3.02x
P/B ratio:
0.95x
Volume:
545.5K
Avg. volume:
657.5K
1-year change:
-31.03%
Market cap:
$420.7M
Revenue:
$138.4M
EPS (TTM):
$0.03

Earnings Data

Next earnings date for GMRE
Aug 06
2025
Most recent earnings per share
$0.03
Beat by $0.02
(May 7/2025)
Consensus Estimate
$0.02
(May 7/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

GMRE Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
08/06/2025 Q2 $35.6M -- -- $0.01 --
05/07/2025 Q1 $35.5M $34.6M $0.03 $0.02 $0.02
02/28/2025 Q4 $34.9M $35M $0.02 -- --
11/06/2024 Q3 $34.6M $34.2M $0.03 -- --
08/06/2024 Q2 $34.3M $34.2M -$0.05 -$0.00 -$0.05
05/07/2024 Q1 $34.7M $35.1M $0.01 $0.01 --
02/27/2024 Q4 $35.8M $32.9M -$0.01 $0.01 -$0.02
11/06/2023 Q3 $36M $35.5M $0.05 -- --
08/02/2023 Q2 $36.5M $36.3M $0.18 $0.02 $0.16
05/03/2023 Q1 -- $36.2M $0.01 -- --
02/28/2023 Q4 -- $36.3M $0.01 -- --
11/02/2022 Q3 -- $35.3M $0.12 -- --
08/03/2022 Q2 -- $33.7M $0.03 -- --
05/04/2022 Q1 -- $31.9M $0.04 -- --
02/28/2022 Q4 -- $30.3M $0.06 -- --
11/03/2021 Q3 -- $30M $0.06 -- --
08/03/2021 Q2 -- $28.2M $0.04 -- --
05/05/2021 Q1 -- $27.3M $0.03 -- --
03/03/2021 Q4 -- $24.9M $0.02 -- --
11/04/2020 Q3 -- $25.1M -$0.22 -- --
08/05/2020 Q2 -- $22M $0.00 -- --
05/06/2020 Q1 -- $21.5M $0.03 -- --
03/04/2020 Q4 -- $20.4M $0.03 -- --
11/06/2019 Q3 -- $18.1M $0.02 -- --
08/07/2019 Q2 -- $16.8M $0.03 -- --
05/08/2019 Q1 -- $15.1M $0.02 -- --
03/06/2019 Q4 -- $14.3M $0.32 -- --
11/05/2018 Q3 -- $14M $0.01 -- --
08/07/2018 Q2 -- $13.2M -$0.00 -- --
05/09/2018 Q1 -- $11.6M $0.02 -- --
03/07/2018 Q4 -- $9.9M -$0.01 -- --
11/09/2017 Q3 -- $8.4M $0.02 -- --
08/10/2017 Q2 -- $7.4M -$0.04 -- --
05/11/2017 Q1 -- $4.6M -$0.07 -- --
12/31/2016 Q4 -- $3.1M -$0.11 -- --
11/10/2016 Q3 -- $1.9M -$0.11 -- --
06/30/2016 Q2 -- $1.8M -$0.35 -- --
03/31/2016 Q1 -- $1.3M -$3.11 -- --
12/31/2015 Q4 -- $656.3K -$3.16 -- --
09/30/2015 Q3 -- $482.1K -$1.99 -- --
06/30/2015 Q2 -- $455.9K -$0.53 -- --

Global Medical REIT Earnings Questions

  • How Much did Global Medical REIT Generate in Revenue Last Quarter?

    Global Medical REIT reported $34.6M worth of top line sales in its most recent quarter.

  • Did Global Medical REIT Beat Earnings Last Quarter?

    Global Medical REIT announced earnings per share of $0.03 which represents a beat of analyst forecast a $0.02 per share.

  • Is Global Medical REIT Profitable?

    Global Medical REIT reported $27M that represents $0.40 per share over the last quarter.

  • What is the Analyst Consensus for Global Medical REIT EPS Next Year?

    Global Medical REIT's earnings are forecast to grow from $0.01 per share to $0.81 per share next year representing an increase of 8200%.

  • When is Global Medical REIT's Earnings Date?

    Global Medical REIT's next earnings date is August 6, 2025.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Palantir Crash?
Will Palantir Crash?

AI and data analytics software major Palantir (NASDAQ:PLTR) has been…

Is Target’s Dividend Worth Buying?
Is Target’s Dividend Worth Buying?

Retail giant Target (NYSE:TGT) has been through an extremely volatile…

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
11
VEON alert for Jun 16

VEON [VEON] is up 4.61% over the past day.

Buy
74
DAVE alert for Jun 16

Dave [DAVE] is up 3.92% over the past day.

Buy
54
DAR alert for Jun 16

Darling Ingredients [DAR] is up 7.19% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock